Stay updated on Lomvastomig vs Nivolumab in Esophageal SCC Clinical Trial
Sign up to get notified when there's something new on the Lomvastomig vs Nivolumab in Esophageal SCC Clinical Trial page.

Latest updates to the Lomvastomig vs Nivolumab in Esophageal SCC Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.5.2 was added to the history. Revision: v3.5.0 was removed from the history.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedNew results have been posted, and the Outcomes Measures, Results, and Study Status sections have been updated.SummaryDifference0.4%

- Check30 days agoChange DetectedAdded Revision: v3.5.0 to the record history and removed Revision: v3.4.3.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded a new site revision entry v3.4.3 and removed the previous v3.4.2 entry from the history.SummaryDifference0.1%

- Check59 days agoChange DetectedA new version entry dated 2026-02-13 was added, with QC status 'Has Not Concluded', and the record history now displays additional sections such as Adverse Events, Outcome Measures, Baseline Characteristics, and Participant Flow.SummaryDifference0.9%

- Check66 days agoChange DetectedAdded a new history entry: Revision: v3.4.2. The deletions remove the funding notice and the prior Revision: v3.4.1 entry.SummaryDifference0.5%

Stay in the know with updates to Lomvastomig vs Nivolumab in Esophageal SCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lomvastomig vs Nivolumab in Esophageal SCC Clinical Trial page.